The SOPHIA study was a randomized phase III study that evaluated margetuximab and chemotherapy compared with trastuzumab and chemotherapy in 530 patients with HER2-positive advanced breast cancer or metastatic breast cancer who had previously received two lines of anti-HER2 therapy [42]. The gene discussed is ERBB2; the disease is breast cancer.